Aficamten Beats Beta-Blockers for HCM Patients
- Aficamten treatment was associated with critically important improvements in exercise capacity and symptoms compared with metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), according to late-breaking research...
- Beta-blockers are commonly used to treat patients with symptomatic obstructive HCM, but they do not directly affect the underlying pathophysiology of the disease and evidence for their efficacy...
- - Doctor Pablo Garcia-Pavia,main inquiry,Puerta de Hierro de Hierro Maxadahonda and National Cardiovascular Research Centre (CNIC),Madrid,spain
“`html
Aficamten Demonstrates Superiority to Metoprolol in Treating Obstructive Hypertrophic Cardiomyopathy
Table of Contents
Aficamten treatment was associated with critically important improvements in exercise capacity and symptoms compared with metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), according to late-breaking research presented at ESC Congress 2025 and simultaneously published in the New England Journal of Medicine.
Beta-blockers are commonly used to treat patients with symptomatic obstructive HCM, but they do not directly affect the underlying pathophysiology of the disease and evidence for their efficacy is limited. Aficamten is a cardiac myosin inhibitor that reduces the damaging hypercontractility associated with obstructive HCM. aficamten improved peak oxygen uptake compared with placebo in patients with persistent symptoms despite beta-blockers in a recent phase III trial but whether aficamten is superior to beta-blockers is unknown. The MAPLE-HCM trial was designed to compare aficamten with metoprolol, as monotherapy, in patients with symptomatic obstructive HCM, some of whom were treatment naïve.
- Doctor Pablo Garcia-Pavia,main inquiry,Puerta de Hierro de Hierro Maxadahonda and National Cardiovascular Research Centre (CNIC),Madrid,spain
understanding Obstructive Hypertrophic Cardiomyopathy (HCM)
Hypertrophic cardiomyopathy (HCM) is a condition where the heart muscle becomes abnormally thick. This thickening can obstruct blood flow out of the heart,leading to symptoms like shortness of breath,chest pain,and fatigue. Obstructive HCM specifically refers to cases where this obstruction is significant. customary treatment often relies on managing symptoms with medications like beta-blockers, but these don’t address the underlying cause of the thickening.
The Role of Cardiac Myosin Inhibition
Aficamten represents a novel approach by directly targeting the underlying pathophysiology of HCM. It works as a cardiac myosin inhibitor,reducing the excessive contraction of the heart muscle. This, in turn, reduces the obstruction and improves the heart’s ability to pump blood effectively.
The MAPLE-HCM Trial: Design and Methodology
This randomized, double-blind, double-dummy phase III trial was conducted across 71 sites in North America,